The company relies on the strong medical resources of shareholders Peking University, Peking University Fangzheng, and Peking University Medical Group to create a next-generation medical service leader; as the group's hospital asset securitization platform, Peking University Pharmaceuticals has a large future market capitalization space and is worthy of long-term attention. We maintained 14-16 EPS of 0.08 yuan, 0.10 yuan, and 0.13 yuan, with year-on-year increases of -35%, 18%, and 27%, corresponding to predicted price-earnings ratios of 225 times, 190 times, and 150 times; if integrated medical mergers and acquisitions were considered, and 2014 was only combined for the fourth quarter, we maintained 14-16 EPS of 0.09 yuan, 0.21 yuan, and 0.27 yuan, with year-on-year increases of -28%, 121%, and 31%, corresponding to predicted price-earnings ratios of 195 times, 88 times, and 68 times; maintaining an increase rating.
【申银万国证券】北大医药:集团目标三年收购10000张医院床位,公司收购一体医疗获股东大会通过
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.